Ellume establishes flagship U.S. manufacturing facility in Maryland

Ellume establishes flagship U.S. manufacturing facility in Maryland

Industry veterans Jeff Boyle, PhD and Dan Mallon will lead Ellume’s U.S. team to support the company’s rapid growth. Ellume establishes state-of-the-art diagnostic manufacturing facility in Frederick, Maryland, which is on track to begin limited operation in second half 2021; The facility was funded by a $231.8 million agreement with the U.S. Department of Defense […]
Read More
Over-the-counter COVID-19 testing now available at CVS Pharmacy

Over-the-counter COVID-19 testing now available at CVS Pharmacy

Retailer expands access to convenient, at-home testing options with new-to-market, home tests available in stores and online. WOONSOCKET, R.I., Monday, April 19, 2021 — CVS Pharmacy, the retail division of CVS Health (NYSE: CVS), today announced the availability of three over-the-counter COVID-19 testing options in stores and online. The tests include the Ellume COVID-19 Home Test, […]
Read More
Ellume and Cambridge Consultants Collaborate on Core Technology Behind Ellume’s Rapid Antigen COVID-19 Test

Ellume and Cambridge Consultants Collaborate on Core Technology Behind Ellume’s Rapid Antigen COVID-19 Test

Cambridge Consultants developed the ground-breaking optics technology powering Ellume’s FDA authorized COVID-19 Home Test CAMBRIDGE, United Kingdom and BRISBANE, Australia, March 10, 2021 Today, digital diagnostics company Ellume highlights the revolutionary technology created in partnership with global product development and technology consultancy firm, Cambridge Consultants, part of the Capgemini Group. Together, the two companies have […]
Read More
Ellume Announces $231.8 Million Agreement with the U.S. Government

Ellume Announces $231.8 Million Agreement with the U.S. Government

The contract includes the delivery of 8.5 million Ellume COVID-19 Home Tests to support the U.S. Government’s pandemic response The investment will support the establishment of Ellume’s first U.S. manufacturing facility, increasing Ellume’s global production capacity by 500,000+ tests per day once completed; The investment extends Ellume’s engagement with the U.S. government following the NIH […]
Read More
Ellume’s COVID-19 Home Test shows 96% accuracy in multi-site US clinical study

Ellume’s COVID-19 Home Test shows 96% accuracy in multi-site US clinical study

Highlights Ellume submits Emergency Use Authorization to the U.S. Food and Drug Administration for the Ellume COVID-19 home test Clinical study demonstrated overall sensitivity of 95% and specificity of 97% Clinically validated for use in symptomatic and asymptomatic users ages 2 years and above Independently run, simulated home-use clinical study of 198 subjects Ellume is […]
Read More
Ellume awarded US$30M from US National Institutes of Health RADx initiative to accelerate development of rapid COVID-19 diagnostics

Ellume awarded US$30M from US National Institutes of Health RADx initiative to accelerate development of rapid COVID-19 diagnostics

Brisbane, Australia — 7 October 2020 Ellume, a leader in rapid digital diagnostics, today announced it was successfully awarded US$30million from the U.S. National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx) initiative to accelerate the clinical testing and manufacturing scale-up of the company’s COVID-19 antigen tests. Ellume’s core fluorescent immunoassay platform has been […]
Read More